DK3358347T3 - Markør til bestemmelse af diabetisk nefropati - Google Patents
Markør til bestemmelse af diabetisk nefropati Download PDFInfo
- Publication number
- DK3358347T3 DK3358347T3 DK16850676.4T DK16850676T DK3358347T3 DK 3358347 T3 DK3358347 T3 DK 3358347T3 DK 16850676 T DK16850676 T DK 16850676T DK 3358347 T3 DK3358347 T3 DK 3358347T3
- Authority
- DK
- Denmark
- Prior art keywords
- marker
- determination
- diabetic nephropathy
- nephropathy
- diabetic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015193638 | 2015-09-30 | ||
| PCT/JP2016/004394 WO2017056498A1 (ja) | 2015-09-30 | 2016-09-29 | 糖尿病性腎症の判定マーカー |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3358347T3 true DK3358347T3 (da) | 2020-11-30 |
Family
ID=58423075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16850676.4T DK3358347T3 (da) | 2015-09-30 | 2016-09-29 | Markør til bestemmelse af diabetisk nefropati |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10802031B2 (da) |
| EP (1) | EP3358347B1 (da) |
| JP (1) | JP6727660B2 (da) |
| CN (1) | CN108291903B (da) |
| DK (1) | DK3358347T3 (da) |
| TW (1) | TWI735470B (da) |
| WO (1) | WO2017056498A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023079706A1 (ja) * | 2021-11-05 | 2023-05-11 | 国立大学法人東北大学 | 糖尿病性腎症の判定方法 |
| CA3241270A1 (en) * | 2021-12-27 | 2023-07-06 | Qinghong LI | Compositions and methods for diagnosing and treating chronic kidney disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3837494B2 (ja) * | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| AU2009203598B2 (en) * | 2008-01-08 | 2013-09-26 | Merck Sharp & Dohme Llc | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide |
| US20100249081A1 (en) * | 2009-03-26 | 2010-09-30 | Ajay Gupta | Compositions and methods for treatment of renal disease |
| CA2772790C (en) * | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| JP2012237623A (ja) | 2011-05-11 | 2012-12-06 | Kureha Corp | 経口投与用吸着剤の投与治療対象の検出方法、及び治療効果の判定方法 |
| WO2013048344A1 (en) | 2011-09-29 | 2013-04-04 | National University Of Singapore | Urinary metabolomic markers for renal insufficiency |
| WO2013188333A1 (en) | 2012-06-13 | 2013-12-19 | Metabolon, Inc. | Biomarkers related to nephrotoxicity and methods using the same |
| JP6128631B2 (ja) | 2012-08-01 | 2017-05-17 | 国立大学法人名古屋大学 | 糖尿病性腎症鑑別用マーカー及びその用途 |
| EP3066476A2 (en) * | 2013-11-04 | 2016-09-14 | The Regents of the University of Michigan | Biomarkers and methods for progression prediction for chronic kidney disease |
| EP3233809B1 (en) * | 2014-12-16 | 2021-04-21 | Signal Pharmaceuticals, LLC | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
-
2016
- 2016-09-29 JP JP2017542754A patent/JP6727660B2/ja active Active
- 2016-09-29 EP EP16850676.4A patent/EP3358347B1/en active Active
- 2016-09-29 CN CN201680068865.9A patent/CN108291903B/zh active Active
- 2016-09-29 DK DK16850676.4T patent/DK3358347T3/da active
- 2016-09-29 WO PCT/JP2016/004394 patent/WO2017056498A1/ja active Application Filing
- 2016-09-29 US US15/763,242 patent/US10802031B2/en active Active
- 2016-09-30 TW TW105131528A patent/TWI735470B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180313851A1 (en) | 2018-11-01 |
| CN108291903B (zh) | 2020-07-28 |
| CN108291903A (zh) | 2018-07-17 |
| JP6727660B2 (ja) | 2020-07-22 |
| TW201715234A (zh) | 2017-05-01 |
| TWI735470B (zh) | 2021-08-11 |
| EP3358347A1 (en) | 2018-08-08 |
| US10802031B2 (en) | 2020-10-13 |
| EP3358347A4 (en) | 2019-05-29 |
| JPWO2017056498A1 (ja) | 2018-08-02 |
| EP3358347B1 (en) | 2020-11-18 |
| WO2017056498A1 (ja) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| CL2016002129A1 (es) | Compuestos de azolina | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3344805T3 (da) | Fremgangsmåde til udvælgelse af aptamerer til ubundne mål | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3201361T3 (da) | Fremgangsmåder til kvantificering af cellefrit DNA | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3386954T3 (da) | Dimere kontrastmidler | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| MA42692A (fr) | Compositions biopharmaceutiques | |
| DK3114235T3 (da) | Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3296597T3 (da) | Krydshovedmotor | |
| DK3597189T3 (da) | Krystallinske forbindelser | |
| DK3331498T3 (da) | Nasalsammensætning | |
| DK3274143T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK2910535T3 (da) | Sammensætning til anvendelse af ekspanderet perlit | |
| DK3120153T3 (da) | Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid |